Skip to Main Content

Labor Day flew by and then summer faded into fall without a word from TG Therapeutics (TGTX) about the outcome of its most important blood cancer drug clinical trial. Results were way past due.

On Tuesday, we learned the reason for the long delay. TG Therapeutics needed all that extra time to gin up an excuse to paper over what is a significant setback and likely failure of its most advanced pipeline effort.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!